Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

Current Medical Research and Opinion

Volumn 22, Issue 7, 2006, Pages 1269-1276

  Schley, Marcus ^a   Legler, Andreas ^a   Skopp, Gisela ^a   Schmelz, Martin ^a   Konrad, Christoph ^a   Rukwied, Roman ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Axon reflex flare; Cannabinoids; Delta 9 THC; Fibromyalgia; Pain

Indexed keywords

DRONABINOL;

ADULT; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; FIBROMYALGIA; HEALTH SURVEY; HUMAN; MALE; MONOTHERAPY; PAIN ASSESSMENT; PSYCHOMETRY; QUESTIONNAIRE; REFLEX; SCORING SYSTEM; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADULT; ANALGESICS, NON-NARCOTIC; AXONS; FEMALE; FIBROMYALGIA; HUMANS; MALE; NEURAL CONDUCTION; PAIN; PILOT PROJECTS; PSYCHOMETRICS; REFLEX; TETRAHYDROCANNABINOL; VASODILATION;

EID: 33746164859     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X112651     Document Type: Article

References (35)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
2. Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain 2002;18:324-36
3. Guhring H, Schuster J, Hamza M, Ates M, et al. HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur J Pharmacol 2001;429:127-34
4. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002;66:243-56
5. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003;102:283-8
6. Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975;15:139-43
7. Neff GW, O'Brien CB, Reddy KR, Bergasa NV, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002;97:2117-9
8. Gonzales-Rosales F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (Dronabinol). J Pain Symptom Manage 1997;14:311-4
9. Beal JE, Olson R, Lefkowitz L, Laubenstein L, et al. Long-term efficacy and safety of Dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997;14:7-14
10. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21
11. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88
12. Schmelz M, Michael K, Weidner C, Schmidt R, et al. Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport 2000;11:645-8
13. Schmelz M, Schmidt R, Ringkamp M, Handwerker HO, et al. Sensitization of insensitive branches of C nociceptors in human skin. J Physiol 1994;480:389-94
14. Sauerstein K, Klede M, Hilliges M, Schmelz M. Electrically evoked neuropeptide release and neurogenic inflammation differ between rat and human skin. J Physiol 2000;529:803-10
15. Koltzenburg M, Lundberg LE, Torebjörk HE. Dynamic and static components of mechanical hyperalgesia in human hairy skin. Pain 1992;51:207-19
16. Skopp G, Potsch L. An investigation of the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples. J Anal Toxicol 2004;28:35-40
17. Koppert W, Dern SK, Sittl R, Albrecht S, et al. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 2001;95:395-402
18. Kjellby-Wendt G, Styf J, Carlsson SG. Early active rehabilitation after surgery for lumbar disc herniation: a prospective, randomized study of psychometric assessment in 50 patients. Acta Orthop Scand 2001;72:518-24
19. Thieme K, Gromnica-Ihle E, Flor H. Operant behavioral treatment of fibromyalgia: a controlled study. Arthritis Rheum 2003;49:314-20
20. Worrel LM, Krahn LE, Sletten CD, Pond GR. Treating fibromyalgia with a brief interdisciplinary program: initial outcomes and predictors of response. Mayo Clin Proc 2001;76:384-90
21. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003;52:238-45
22. Johanek LM, Simone DA. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 2004;109:432-42
23. Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000;57:288-95
24. Steinhoff M, Stander S, Seeliger S, Ansel JC, et al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003;139:1479-88
25. Schmelz M, Zeck S, Raithel M, Rukwied R. Mast cell tryptase in dermal neurogenic inflammation. Clin Exp Allergy 1999;29:652-9
26. Khasabova IA, Harding-Rose C, Simone DA, Seybold VS. Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. J Neurosci 2004;24:1744-53
27. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74:1317-24
28. Koppert W, Angst M, Alsheimer M, Sittl R, et al. Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Pain 2003;106:91-9
29. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 2005;102:3093-8
30. Buggy DJ, Toogood L, Maric S, Sharpe P, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003;106:169-72
31. Johanek LM, Heitmiller DR, Turner M, Nader N, et al. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 2001;93:303-15
32. Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002;28:181-99
33. Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48:1420-9
34. Dirks J, Petersen KL, Rowbotham MC, Dahl JB. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology 2002;97:102-7
35. Russo EB. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 2004; 25:31-9